Results 191 to 200 of about 108,162 (245)
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller +9 more
wiley +1 more source
Australian Rural Surgical Workforce: A Policy Analysis. [PDF]
Carmichael GJ +5 more
europepmc +1 more source
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers. [PDF]
Güzel HG +4 more
europepmc +1 more source
Direct healthcare costs associated with reported patient safety incidents in two tertiary hospitals in Colombia. [PDF]
Acevedo-Peña JR +9 more
europepmc +1 more source
MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination. [PDF]
Jiménez-González C +7 more
europepmc +1 more source
Insights on unmet needs from a survey among social media editors by EMEUNET. [PDF]
Gupta L +9 more
europepmc +1 more source

